US EditionPublished • loading... • Updated
Precigen, Inc. (PGEN) Stock Analysis: Unpacking The 100% Upside Potential
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Precigen, Inc. (PGEN) Stock Analysis: Unpacking The 100% Upside Potential
In the ever-evolving world of biotechnology, Precigen, Inc. (NASDAQ: PGEN) stands out as a compelling player, particularly with its ambitious focus on gene and cell therapies targeting critical health issues such as cancer and autoimmune disorders. With a market cap of $1.5 billion, Precigen, headquartered in Germantown, Maryland, is making significant strides in the healthcare sector. Currently trading at $4.24, Precigen’s stock has shown resil…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
